[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-rhythm-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-rhythm-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100525995","phase-2-withdrawal-of-treatment-for-heart-failure-patients-with-recovery-from-tachycardia-induced-cardiomyopathy-100525995",false,"NCT06128980","Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy","Withdrawal of Pharmacological Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy - WEAN-HF","WEAN-HF","Inclusion Criteria:\n\nPatients with new onset heart failure (ambulatory or hospital) with reduced ejection fraction (LVEF≤40% assessed by echocardiography) and NYHA ≥2 and atrial fibrillation or atrial flutter with ventricular rate ≥110 bpm (ECG monitoring, hospital telemetry or Holter monitoring) that following GDMT - while AF is terminated (e.g. ablation or conversion) or controlled (HR\\\u003C110 on resting ECG) - experience LVEF remission (LVEF ≥50%), normalization of indexed LV volume, and normal ECG (no bundle branch block, ST segment deviations or T-wave inversion) and NT-proBNP \\\u003C250 pg\u002Fml.\n\nExclusion Criteria:\n\n* 18 years or older and able to consent\n* Former ablation procedures and inability to tolerate antiarrhythmic drugs\n* Pregnancy\n* Congenital heart disease (congenital defects with no hemodyamic effects are not excluded)\n* Previously genotyped positive for genes known to cause cardiomyopathy\n* Probable hypertrophic, restrictive or non-compaction cardiomyopathy\n* Moderate\u002Fsevere valvular disease\n* Suspicion of or known cardiac amyloidosis, sarcoidosis, or other storage\u002Finflammatory disease\n* More than 10% PVCs or documented sustained ventricular arrhythmias\n* History of persistent or permanent AF with ventricular rates \\>110 before incident HF despite best standard of care\n* eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n* Acute myocardial infarction at index\n* Probable medication-, alcohol- or illicit drug use induced AF and\u002For HF\n* Systolic blood pressure \\>160 mmHg (at multiple measurements) at index or history of uncontrollable hypertension\n* Myocarditis\n* Cardiogenic shock at index\n* Aborted sudden cardiac death\n* Pacing-induced cardiomyopathy\n* 1.st degree relative with DCM","ALL","18 Years",{"count":20,"type":21},348,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","New onset heart failure (HF) is observed in up to 25% of patients with incident atrial fibrillation or flutter (AF). Current guidelines suggest that both conditions (AF \\& HF) be addressed with guideline directed medical therapy (GDMT) for HF and rate or rhythm control of AF. Hence, patients with both conditions are subjected to extensive polypharmacy with possible prognostic benefits, but also possible side effects, such as decreased renal function, dizziness, tiredness and hypotension, as well as the financial burden on both the individual patients and society, in addition to the stigma of having a HF diagnosis.\n\nGuidelines do not inform how to manage long-term patients with HF, who following control of the incident tachycardia (e.g. AF), show full recovery from their HF condition.\n\nThis investigator-initiated, open-label, randomized, non-inferiority trial will test whether incremental weaning of GDMT in patients following full cardiac recovery and AF control is non-inferior compared to continuous GDMT with respect to the primary endpoint of freedom from heart failure deterioration. Furthermore, this study seeks to extensively phenotype these patients (genetic testing, advanced imaging, biomarkers etc.) in order to establish whether certain phenotypes are at lesser or greater risk of deterioration once remission is established. This novel approach of a personalized treatment regimen depending on e.g. genetic profiling could lead to an aggressive treatment in patients at high risk of deterioration and conversely spare patients with a negligible risk, a life-long intensive treatment regimen.\n\nAll HF clinics located in Zealand, Denmark, with a catchment area of \\>2 million citizens, have agreed to participate in the WEAN-HF trial. A total of 348 patients will be randomized. Patients are followed up the 1st year after randomization with clinical examination, biomarkers and echocardiography, and are subsequently followed via Danish nationwide registries for 10 years.",[28,29],"Heart Failure With Reduced Ejection Fraction","Heart Rhythm Disorder","RECRUITING","2026-02-20",{"date":33,"type":34},"2026-02-23","ACTUAL",{"date":36,"type":34},"2025-01-09",{"date":38,"type":21},"2032-01",{"name":40,"class":41},"Herlev and Gentofte Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100573121","role-of-ivabradine-for-heart-rate-control-in-management-of-patients-with-sepsis-and-septic-shock-100573121","NCT06742164","Role of Ivabradine for Heart Rate Control in Management of Patients With Sepsis and Septic Shock","Inclusion Criteria:\n\n* Patients with proven or suspected site of infection.\n* Patients sepsis (acute organ dysfunction secondary to documented or suspected infection)\n* Patients with septic shock (defined as hypotension unresponsive to fluid resuscitation and requiring vasopressor treatment to maintain adequate blood pressure) for at least 6 hours and less than 24 hours.\n* Patients with sinus rhythm with heart rate ≥ 95 bpm at time of randomization. Informed consent obtained in accordance with local regulations.\n\nExclusion Criteria:\n\n* Cardiac arrhythmia, conduction disorder, sinus syndrome (\"sick sinus syndrome\"), atrial fibrillation and heart block.\n* Cardiogenic shock or acute heart failure, without proven or suspected infection.\n* Acute coronary syndrome.\n* Refractory shock with systolic arterial pressure \\\u003C90 mm Hg despite the use of high doses of vasopressors.\n* Co-treatment with drugs inducing bradycardia.\n* Patients with pacemakers.\n* Known pregnancy, breast-feeding, women with of childbearing potential will be tested for pregnancy and excluded if pregnant.\n* Known allergy to Ivabradine\n* Severe renal failure (creatinine clearance \\\u003C15 ml\u002Fmin) or hepatic failure (prothrombin time \\\u003C20%)\n* Tachycardia due to hyperthyroidism, pheochromocytoma or severe anemia (\\\u003C7 g\u002Fdl)\n* Enteral feeding impossible.",{"count":50,"type":21},76,[52],"NA","Tachycardia is associated with excess mortality during septic shock. This may be related to the increase in cardiac metabolic demand, impaired cardiac diastolic function and less effect of administered exogenous catecholamines.\n\nIn this study, we evaluate the effect of enteral Ivabradine on outcome of septic patients regarding need for vasopressor therapy, mechanical ventilation, renal replacement therapy, length of ICU stay and in-hospital mortality.",[29],"NOT_YET_RECRUITING","2024-12-16",{"date":58,"type":34},"2024-12-19",{"date":60,"type":21},"2024-12-30",{"date":62,"type":21},"2025-06-30",{"name":64,"class":41},"Ain Shams University"]